X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (297) 297
Book Review (97) 97
Publication (15) 15
Book Chapter (12) 12
Conference Proceeding (6) 6
Dissertation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
immuno-oncology (281) 281
immunotherapy (133) 133
oncology (129) 129
index medicus (121) 121
cancer (110) 110
humans (89) 89
immunology (42) 42
tumors (41) 41
melanoma (40) 40
chemotherapy (33) 33
pharmacology & pharmacy (32) 32
animals (30) 30
immunotherapy - methods (30) 30
clinical trials (28) 28
neoplasms - immunology (28) 28
ipilimumab (27) 27
nivolumab (27) 27
review (27) 27
cancer therapies (26) 26
immune checkpoint (25) 25
therapy (25) 25
biomarkers (24) 24
patients (24) 24
metastasis (23) 23
open-label (23) 23
care and treatment (22) 22
neoplasms - therapy (21) 21
pd-1 (21) 21
research (21) 21
analysis (20) 20
cell lung-cancer (20) 20
expression (20) 20
immune response (20) 20
medicine & public health (20) 20
antigens (19) 19
pembrolizumab (19) 19
apoptosis (18) 18
cancer immunotherapy (18) 18
lung cancer (18) 18
lymphocytes (18) 18
pd-l1 (18) 18
t cells (18) 18
antineoplastic agents - therapeutic use (17) 17
checkpoint inhibitors (17) 17
chemistry, medicinal (17) 17
female (17) 17
gene expression (17) 17
medical research (17) 17
mice (17) 17
survival (17) 17
t-cells (17) 17
tumor microenvironment (17) 17
immune system (16) 16
lymphocytes t (16) 16
male (15) 15
medicine, research & experimental (15) 15
metastases (15) 15
metastatic melanoma (15) 15
precision medicine (15) 15
usage (15) 15
cancer-immunotherapy (14) 14
middle aged (14) 14
neoplasms. tumors. oncology. including cancer and carcinogens (14) 14
regulatory t-cells (14) 14
aged (13) 13
blockade (13) 13
cytotoxicity (13) 13
health aspects (13) 13
immuno‐oncology (13) 13
neoplasms - drug therapy (13) 13
pd-1 blockade (13) 13
solid tumors (13) 13
advanced melanoma (12) 12
cell death (12) 12
ctla-4 (12) 12
dendritic cells (12) 12
hematology (12) 12
immune checkpoint inhibitor (12) 12
immunohistochemistry (12) 12
inhibitors (12) 12
monoclonal antibodies (12) 12
prognosis (12) 12
programmed cell death 1 receptor - antagonists & inhibitors (12) 12
adult (11) 11
antibodies (11) 11
antibody (11) 11
antitumor immunity (11) 11
cancer research (11) 11
drugs (11) 11
genetic aspects (11) 11
kinases (11) 11
pd-l1 protein (11) 11
pharmacology (11) 11
safety (11) 11
survival analysis (11) 11
vaccines (11) 11
antibodies, monoclonal - therapeutic use (10) 10
cells (10) 10
docetaxel (10) 10
immune checkpoint blockade (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


ACS Medicinal Chemistry Letters, ISSN 1948-5875, 05/2017, Volume 8, Issue 5, pp. 486 - 491
A data-centric medicinal chemistry approach led to the invention of a potent and selective IDO1 inhibitor , INCB24360 (epacadostat). The molecular structure of... 
Epacadostat | data-centric medicinal chemistry | immuno-oncology | INCB24360 | IDO1
Journal Article
Methods in Enzymology, ISSN 0076-6879, 2019
Emergency of the CRISPR technology, a new genome editing tool, revolutionized the biomedical research field in the past 6 years. At the same time, recent... 
CRISPR | CAR-T | sgRNA | Immunotherapy | dCas9 | Cas9 | Immuno-oncology | Cancer
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2018, Volume 29, Issue 11, pp. 2208 - 2213
Abstract Background A nivolumab monotherapy flat-dosing regimen of 480 mg every 4 weeks (Q4W) has been approved in several markets, including the United... 
PK exposure | Safety | Solid tumors | Q4W | Immuno-oncology | Nivolumab | nivolumab | ONCOLOGY | safety | immuno-oncology | CELL | DOCETAXEL | solid tumors | CHEMOTHERAPY | Life Sciences | Original
Journal Article
Annals of Oncology, ISSN 0923-7534, 12/2017, Volume 28, Issue 12, pp. 2977 - 2984
Background: Novel immune checkpoint blockade strategies are being evaluated in clinical trials and include targeting the lymphocyte activation gene 3 (LAG-3)... 
Immunohistochemistry | Breast cancer | Immune checkpoints | LAG-3 | Immuno-oncology | ONCOLOGY | ESTROGEN | breast cancer | ANTIBODY | immuno-oncology | immunohistochemistry | immune checkpoints | Index Medicus
Journal Article
Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 07/2018, Volume 143, Issue 14, pp. 1022 - 1029
Journal Article
Oncotarget, ISSN 1949-2553, 01/2019, Volume 10, Issue 2, pp. 209 - 215
Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) mutation benefit from a first line of treatment with tyrosine kinase... 
EGFR mutation | Chemotherapy | NSCLC | Immuno-oncology | Immunotherapy
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 11/2018, Volume 13, Issue 11, pp. 1771 - 1775
Introduction: Checkpoint inhibitors augment the immune system's natural surveillance mechanisms and have increasing applications in NSCLC. Immunosuppressive... 
immuno-oncology | corticosteroids | nivolumab | NSCLC | CELL LUNG-CANCER | ONCOLOGY | RESPIRATORY SYSTEM | DOCETAXEL
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 17, pp. 13593 - 13611
The adenosine receptor (AR) subtypes A2A and A2B are rhodopsin-like Gs protein-coupled receptors whose expression is highly regulated under pathological, e.g.... 
Receptor heteromerization | G protein-coupled receptor (GPCR) | Adenosine receptors (ARs) | Pharmacology | Immuno-oncology
Journal Article
Experimental Biology and Medicine, ISSN 1535-3702, 2019, pp. 1535370219855970 - 1535370219855970
Journal Article
Bulletin of Siberian Medicine, ISSN 1682-0363, 05/2019, Volume 18, Issue 1, pp. 60 - 75
Interrelationship between a malignant tumor and the immunity are provided by the involvement of both adaptive and innate immune systems. Monocytes are major... 
immuno-oncology | prognosis | monocyte subpopulations | cancer immunotherapy
Journal Article
by Thorsson, Vesteinn and Thorsson, Vésteinn and Gibbs, Richard A and Gibbs, David L and Brown, Scott D and Wolf, Gregory and Wolf, Denise and Bortone, Dante S and Ou Yang, Tai-Hsien and Porta-Pardo, Eduard and Gao, Galen F and Gao, Jianjiong and Plaisier, Christopher L and Eddy, James A and Ziv, Elad and Culhane, Aedin C and Paull, Evan O and Sivakumar, I.K. Ashok and Gentles, Andrew J and Malhotra, Raunaq and Farshidfar, Farshad and Colaprico, Antonio and Parker, Joel S and Mose, Lisle E and Vo, Nam Sy and Liu, Wenbin and Liu, Jianfang and Liu, Jia and Liu, Yuexin and Liu, Xiuping and Rader, Janet and Dhankani, Varsha and Reynolds, Sheila and Reynolds, Sheila M and Bowlby, Reanne and Califano, Andrea and Cherniack, Andrew D and Anastassiou, Dimitris and Bedognetti, Davide and Mokrab, Younes and Newman, Aaron M and Rao, Arvind and Chen, Amy and Chen, Chu and Chen, Ken and Krasnitz, Alexander and Hu, Jianhong and Hu, Hai and Malta, Tathiane M and Noushmehr, Houtan and Pedamallu, Chandra Sekhar and Bullman, Susan and Ojesina, Akinyemi I and Lamb, Andrew and Zhou, Wanding and Shen, Hui and Choueiri, Toni K and Weinstein, John N and Guinney, Justin and Saltz, Joel and Holt, Robert and Holt, Robert A and Rabkin, Charles S and Caesar-Johnson, Samantha J and Demchok, John A and Felau, Ina and Kasapi, Melpomeni and Ferguson, Martin L and Hutter, Carolyn M and Sofia, Heidi J and Tarnuzzer, Roy and Wang, Jioajiao and Wang, Min and Wang, Linghua and Wang, Zhining and Wang, Timothy and Wang, Jing and Yang, Ju Dong and Yang, Hannah and Yang, Liming and Yang, Ian and Zenklusen, Jean C and Zhang, Jiashan (Julia) and Zhang, Jiexin and Zhang, Lizhi and Zhang, Wei and Zhang, Hongzheng and Zhang, Hailei and Zhang, Hongxin and Chudamani, Sudha and Lolla, Laxmi and Naresh, Rashi and Pihl, Todd and Sun, Yichao and Sun, Qiang and Wan, Yunhu and Wu, Ye and Cho, Juok and DeFreitas, Timothy and Frazer, Scott and ... and Canc Genome Atlas Res Network and Cancer Genome Atlas Research Network
Immunity, ISSN 1074-7613, 04/2018, Volume 48, Issue 4, pp. 812 - 830.e14
We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across... 
tumor immunology | immunotherapy | cancer genomics | integrative network analysis | immuno-oncology | tumor microenvironment | immune subtypes | immunomodulatory | GENOMIC ANALYSES | INFORMATION | T-CELL-RECEPTOR | REGULATORY NETWORK | CLASSIFICATION | IMMUNOLOGY | SEQUENCING DATA | SOMATIC MUTATIONS | COMPREHENSIVE ANALYSIS | PREDICTION | REVEALS | Transforming Growth Factor beta - immunology | Prognosis | Humans | Middle Aged | Th1-Th2 Balance - physiology | Male | Neoplasms - classification | Wound Healing - immunology | Young Adult | Transforming Growth Factor beta - genetics | Neoplasms - genetics | Neoplasms - immunology | Interferon-gamma - immunology | Adolescent | Aged, 80 and over | Adult | Female | Aged | Interferon-gamma - genetics | Wound Healing - genetics | Genomics - methods | Child | Macrophages - immunology | Cell proliferation | Cluster analysis | Transcription | Copy number | p53 Protein | Lung cancer | Genomics | Aneuploidy | Lymphocytes T | Genomes | Cell interactions | Macrophages | Immunotherapy | DNA methylation | Deoxyribonucleic acid--DNA | Immune system | Medical research | Wound healing | Immunomodulation | MiRNA | Stockholders | Inflammation | T cell receptors | Communications networks | Gene expression | White blood cells | Inventors | Medical prognosis | γ-Interferon | Mutation | Cancer | Tumors | Index Medicus | Immune Subtypes | Integrative Network Analysis | Cancer Genomics | Immuno-oncology | Tumor immunology
Journal Article
Annals of Oncology, ISSN 0923-7534, 04/2019, Volume 30, Issue 4, pp. 644 - 651
Abstract Background A nivolumab dosage regimen of 480 mg intravenously (i.v.) every 4 weeks (Q4W) was approved by FDA for the majority of the approved... 
nivolumab | ONCOLOGY | Q4W dosing frequency | regulatory perspective | clinical pharmacology | immuno-oncology | model-informed drug development | CANCER | PROGRESSION
Journal Article
ACS MEDICINAL CHEMISTRY LETTERS, ISSN 1948-5875, 05/2017, Volume 8, Issue 5, pp. 486 - 491
A data-centric medicinal chemistry approach led to the invention of a potent and selective IDO1 inhibitor 41, INCB24360 (epacadostat). The molecular structure... 
TARGET | CHEMISTRY, MEDICINAL | INDOLEAMINE 2,3-DIOXYGENASE | DRUG DISCOVERY | Epacadostat | data-centric medicinal chemistry | TRYPTOPHAN CATABOLISM | COMBINATIONS | METABOLISM | IDO | immuno-oncology | ANTITUMOR IMMUNITY | TUMORAL IMMUNE RESISTANCE | INCB24360 | IPILIMUMAB | IDO1
Journal Article
Pathologe, ISSN 0172-8113, 11/2018, Volume 39, Issue 6, pp. 498 - 519
Journal Article
OncoImmunology, ISSN 2162-4011, 05/2016, Volume 5, Issue 5, pp. e1143997 - e1143997
Background: Untreated metastatic uveal melanoma (UM) carries a grave prognosis. Unlike cutaneous melanoma (CM), there are no established treatments known to... 
metastases | Pembrolizumab | immuno-oncology | Anti-PD-1 | uveal melanoma | Uveal melanoma | Immuno-oncology | Metastases | CRITERIA | TRIALS | IMMUNOLOGY | CANCER | TUMORS | METASTATIC MELANOMA | ONCOLOGY | NIVOLUMAB | immunooncology
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 02/2018, Volume 28, Issue 4, pp. 732 - 736
A novel series of -phenylenediamine-based inhibitors of indoleamine 2,3-dioxygenase (IDO) has been identified. Compound 19 demonstrated significant potency in... 
Kynurenine | Indoleamine 2,3-dioxygenase | IDO |